{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.61","value":"12.22"},{"groupId":"OG001","spread":"4.08","value":"29.53"},{"groupId":"OG002","spread":"6.26","value":"33.72"},{"groupId":"OG003","spread":"6.85","value":"41.06"},{"groupId":"OG004","spread":"20.05","value":"32.42"},{"groupId":"OG005","spread":"25.82","value":"47.89"},{"groupId":"OG006","spread":"11.48","value":"40.93"},{"groupId":"OG007","spread":"34.02","value":"41.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"6"}],"units":"Participants"}],"title":"Tisotumab Vedotin: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.50","value":"13.54"},{"groupId":"OG001","spread":"39.89","value":"23.50"},{"groupId":"OG002","spread":"1.74","value":"33.68"},{"groupId":"OG003","spread":"4.69","value":"40.44"},{"groupId":"OG004","spread":"14.50","value":"33.62"},{"groupId":"OG005","spread":"62.74","value":"32.15"},{"groupId":"OG006","spread":"23.15","value":"39.89"},{"groupId":"OG007","spread":"5.61","value":"48.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"}],"units":"Participants"}],"title":"Tisotumab Vedotin: Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.93","value":"16.05"},{"groupId":"OG001","spread":"30.64","value":"28.66"},{"groupId":"OG002","spread":"7.48","value":"42.52"},{"groupId":"OG003","spread":"8.65","value":"57.37"},{"groupId":"OG004","spread":"34.62","value":"42.72"},{"groupId":"OG005","spread":"17.47","value":"57.72"},{"groupId":"OG006","spread":"5.32","value":"54.95"},{"groupId":"OG007","spread":"27.36","value":"55.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"6"}],"units":"Participants"}],"title":"Total HuMax-TF: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.73","value":"18.34"},{"groupId":"OG001","spread":"27.65","value":"30.71"},{"groupId":"OG002","spread":"4.27","value":"40.37"},{"groupId":"OG003","spread":"9.60","value":"56.77"},{"groupId":"OG004","spread":"25.39","value":"42.18"},{"groupId":"OG005","spread":"53.11","value":"46.24"},{"groupId":"OG006","spread":"9.18","value":"51.06"},{"groupId":"OG007","spread":"10.07","value":"66.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"}],"units":"Participants"}],"title":"Total HuMax-TF: Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"6"}],"units":"Participants"}],"description":"PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. t1/2 was only analyzed for the dose escalation part of the study. Data was not planned to be collected for t1/2 of tisotumab vedotin and total HuMax-TF for the dose expansion part.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.","id":"OG000","title":"Dose Escalation Part: 0.3 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.","id":"OG001","title":"Dose Escalation Part: 0.6 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.","id":"OG002","title":"Dose Escalation Part: 0.9 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.","id":"OG003","title":"Dose Escalation Part: 1.2 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.","id":"OG004","title":"Dose Escalation Part: 1.5 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.","id":"OG005","title":"Dose Escalation Part: 1.8 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG006","title":"Dose Escalation Part: 2.0 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.","id":"OG007","title":"Dose Escalation Part: 2.2 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set: all participants who had been exposed to tisotumab vedotin and had at least 1 PK assessment after first dose.","reportingStatus":"POSTED","timeFrame":"Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)","title":"Dose Escalation Part: Half-life (t1/2) of Tisotumab Vedotin and Total HuMax-TF","type":"SECONDARY","unitOfMeasure":"hours"}